Molecular target
HCV NS5A Protein / NS5B Polymerase
Nonstructural HCV proteins essential for viral replication. NS5A inhibitors (velpatasvir, ledipasvir, pibrentasvir) and NS5B polymerase inhibitors (sofosbuvir) form the basis of modern Direct-Acting Antiviral (DAA) regimens that achieve >95% sustained virologic response in 8-12 weeks — among the great pharmaceutical successes of the 2010s.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on HCV NS5A Protein / NS5B Polymerase
These medications have HCV NS5A Protein / NS5B Polymerase among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.